title: Immunotherapy: opportunities, risks and future perspectives.
abstract: This review is intended to reflect upon the current status and perspectives of cell-based immunotherapy at a time when the promise of extensive pre-clinical research has been translated into encouraging clinical responses. However, some of these have also been complicated by significant adverse reactions. As the field moves towards definitive late stage trials, with a growing interest from pharmaceutical companies, we realize that novel cell therapy strategies pose questions that are familiar to traditional drug development, along with new considerations due to the potential of T cells to persist long term and to expand after adoptive transfer. These questions address the safety of the product, the efficacy, the mode of action, and the anticipation of risks. From different perspectives, we intend to address exciting opportunities and safety concerns in current concepts of cellular immunotherapy.
authors.affiliation: Technical University Munich, Faculty of Medicine, TUMCells Interdisciplinary Center for Cellular Therapies, Munich, Germany. Electronic address: martin.hildebrandt@lrz.tum.de.
authors.forename: Martin
authors.initials: M
authors.lastname: Hildebrandt
authors.affiliation: University College Hospital, Research Department of Hematology, London, United Kingdom.
authors.forename: Karl
authors.initials: K
authors.lastname: Peggs
authors.affiliation: Charité Universitaetsmedizin Berlin, Department of Hematology and Oncology, Berlin, Germany.
authors.forename: Lutz
authors.initials: L
authors.lastname: Uharek
authors.affiliation: Children's National Health System, Center for Cancer and Immunology Research, Washington, DC, USA.
authors.forename: Catherine M
authors.initials: CM
authors.lastname: Bollard
authors.affiliation: Baylor College of Medicine and Pediatrics, Houston, Texas, USA.
authors.forename: Helen E
authors.initials: HE
authors.lastname: Heslop
mesh_terms: D019496:Cancer Vaccines / Q000627:therapeutic use; D064987:Cell- and Tissue-Based Therapy / Q000639:trends*; D002986:Clinical Trials as Topic; D015316:Genetic Therapy / Q000639:trends*; D006801:Humans; D007167:Immunotherapy / Q000639:trends*; D011948:Receptors, Antigen, T-Cell / Q000235:genetics / Q000276:immunology*; D013045:Species Specificity
chemical_list: D019496:Cancer Vaccines; D011948:Receptors, Antigen, T-Cell
keywords: T cell receptor; clinical trials; gene therapy; immunotherapy; safety; treatment efficacy